Renata M. Kisa

Publications by Year

Research Areas

Psoriasis: Treatment and Pathogenesis, Cytokine Signaling Pathways and Interactions, Health Systems, Economic Evaluations, Quality of Life, Synthesis and biological activity, Pharmaceutical studies and practices

Most-Cited Works

• → Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)(2014)107 cited
• → Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in a large commercially insured population in the United States: A retrospective cohort study(2016)106 cited
• → Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial(2022)47 cited
• → Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2)(2024)40 cited
• → Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years(2024)32 cited
• → Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis(2023)32 cited
• → BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients(2020)7 cited
• → Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary(2023)5 cited
• → Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials(2022)4 cited
• → Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials(2024)4 cited